Robyn Leitner, MD
Urology · Manasquan, NJNPI 1659342277
Payments from drug & device makers
Across 163 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$385
- Axonics, Inc.$249
- Medtronic$239
- Calyxo, Inc.$228
- Boston Scientific$226
- EDAP Technomed Inc$198
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,438100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $385 |
| Axonics, Inc. | 11 | $249 |
| Medtronic(2 entities) | 4 | $239 |
| Calyxo, Inc. | 4 | $228 |
| Boston Scientific | 6 | $226 |
| EDAP Technomed Inc | 1 | $198 |
| Johnson & Johnson | 13 | $184 |
| Tolmar, Inc. | 9 | $149 |
| Coloplast | 7 | $124 |
| Astellas Pharma US Inc | 8 | $119 |
| 180 Medical, Inc. | 6 | $114 |
| Myovant Sciences Inc. | 3 | $112 |
| Ferring Pharmaceuticals Inc. | 6 | $88 |
| Sumitomo Pharma America, Inc. | 5 | $86 |
| Immunitybio, Inc. | 4 | $72 |
| Dentsply IH AB | 2 | $66 |
| Urogen Pharma, Inc. | 4 | $66 |
| Myriad Genetic Laboratories, Inc. | 4 | $63 |
| ABC Home Medical Supply, Inc. | 2 | $60 |
| Dendreon Pharmaceuticals LLC | 3 | $58 |
| Teleflex LLC | 3 | $57 |
| Pfizer | 4 | $54 |
| Neotract Inc. | 3 | $50 |
| Hollister Incorporated | 3 | $49 |
| Bioprotect Medical, Inc. | 2 | $48 |
| Tolmar Pharmaceuticals, Inc. | 3 | $38 |
| Merck | 2 | $34 |
| Bayer | 2 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $29 |
| Acerus Pharmaceuticals Corporation | 2 | $28 |
| Urovant Sciences Inc | 2 | $27 |
| Agiliti Surgical, Inc. | 1 | $26 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Dentsply IH Inc. | 1 | $19 |
| Mission Pharmacal Company | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$230
- FOCAL ONE$198
- CVAC Aspiration System$140
- Bulkamid$128
- INTERSTIM$106
How this compares
$3,453 in reported general payments places this provider in the 60th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 461 | $400,573 |
| GemtesaVibegron | 125 | $110,320 |
| ElmironPentosan Polysulfate Sodium | 29 | $36,573 |
| Methenamine Hippurate | 516 | $19,489 |
| Solifenacin Succinate | 448 | $17,024 |
| Mirabegron ErMirabegron | 12 | $8,700 |
| NitrofurantoinNitrofurantoin Macrocrystal | 214 | $6,863 |
| Tamsulosin Hcl | 356 | $6,521 |
| Estradiol | 99 | $6,095 |
| Oxybutynin Chloride ErOxybutynin Chloride | 220 | $5,238 |
| Potassium Citrate ErPotassium Citrate | 55 | $4,597 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 24 | $4,406 |
| Testosterone | 11 | $3,527 |
| Tolterodine Tartrate ErTolterodine Tartrate | 69 | $3,243 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 341 | $3,074 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $119 | $400,573461 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $86 | $110,320125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 401 urology providers in New Jersey.
Other urology in Manasquan
- Gordon BrownCherry Hill$2.8M
- Nitin YerramHackensack$1.6M
- Michael StifelmanHackensack$1.5M
- Thomas MuellerLinwood$1.2M
- David SussmanLinwood$833K
- Michael IngberDenville$607K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$464K
- Neil ShermanCranford$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.